Late INa Inhibition as an Antiarrhythmic Strategy

Alexander Burashnikov1

  • 1*Lankenau Institute for Medical Research, Wynnewood, PA; and †Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA.

Insights

Targeting the late sodium channel current (late INa) offers antiarrhythmic benefits by reducing intracellular sodium and calcium, and normalizing heart repolarization. Specific late INa inhibition is most effective for arrhythmias linked to prolonged repolarization.

Area of Science:

  • Cardiovascular Physiology
  • Electrophysiology
  • Pharmacology

Background:

  • The late sodium channel current (late INa) is a recognized target for antiarrhythmic therapies.
  • Its inhibition is proposed to work by suppressing calcium-mediated arrhythmias and normalizing cardiac repolarization.

Purpose of the Study:

  • To elucidate the antiarrhythmic mechanisms of late INa inhibition.
  • To define the conditions and limitations for specific late INa blockade.

Main Methods:

  • Review and analysis of existing literature on late INa function and pharmacology.
  • Examination of the interplay between late INa density, heart rate, and cardiac repolarization.

Main Results:

  • Late INa inhibition can suppress intracellular calcium overload and normalize repolarization, key antiarrhythmic effects.
  • Endogenous late INa is typically small, but its contribution to sodium loading is significant under specific conditions (e.g., bradycardia, prolonged repolarization).
  • Specific late INa blockade is feasible at slower heart rates, but sodium channel blockers may also inhibit peak INa at rapid rates.

Conclusions:

  • Specific inhibition of late INa holds promise for preventing arrhythmias associated with prolonged cardiac repolarization.
  • The antiarrhythmic potential may extend to various arrhythmias characterized by elongated repolarization.

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
3.8K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.7K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.4K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.1K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.6K